BP1.3656B |
Katalog-Nr.GC79291
One-Click Copy Product Info
|
BP1.3656B is a selective, orally active, blood-brain barrier-permeable histamine H3 receptor ( histamine H3 receptor ) inverse agonist/antagonist, with a K B value of 0.08 nM for antagonizing agonist-induced activity and an IC50 value of 0.38 nM for directly inhibiting the basal activity of the receptor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 914302-78-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, BP1.3656B (0.003-1 mg/kg; p.o.; single administration) dose-dependently increases the level of t-MeHA in the brain of male OF1 mice, with an ED50 of 0.008 mg/kg[1]. BP1.3656B (0.03-0.1 mg/kg; i.p.; single administration) dose-dependently increases extracellular acetylcholine levels in the hippocampus of male Wistar rats[1]. BP1.3656B (0.005-0.3 mg/kg; single administration) reduces alcohol-induced motor hyperactivity in female DBA/2J mice[1]. BP1.3656B (0.3 mg/kg; i.p.; once daily for 4 consecutive days) reduces alcohol-induced locomotor sensitization in female DBA/2J mice by 31%-44% over the 4-day treatment course[1]. BP1.3656B (0.3 mg/kg; i.p.; single administration) reduces alcohol intake by 25% in male mice in the dark drinking model, normalizes anxiety-like behaviors in mice during alcohol withdrawal, and decreases voluntary alcohol intake in non-addicted and alcohol-dependent male rats[1].
References:
[1]. Le Foll B, et al. Histamine H3 Receptor as a target for alcohol use disorder: challenging the predictability of animal models for clinical translation in drug development. Transl Psychiatry. 2026;16(1):55. Published 2026 Jan 29.
| Cas No. | 914302-78-6 | SDF | |
| Formula | C20H28Cl2N2O2 | M.Wt | 399.35 |
| Löslichkeit | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5041 mL | 12.5203 mL | 25.0407 mL |
| 5 mM | 500.8 μL | 2.5041 mL | 5.0081 mL |
| 10 mM | 250.4 μL | 1.252 mL | 2.5041 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)